BMP-13 Emerges as a Potential Inhibitor of Bone Formation by Shen, Bojiang et al.
Int. J. Biol. Sci. 2009, 5 
 
 
http://www.biolsci.org 
192
I In nt te er rn na at ti io on na al l   J Jo ou ur rn na al l   o of f   B Bi io ol lo og gi ic ca al l   S Sc ci ie en nc ce es s   
2009; 5(2):192-200 
© Ivyspring International Publisher. All rights reserved 
Short Research Communication 
BMP-13 Emerges as a Potential Inhibitor of Bone Formation 
Bojiang Shen1 
, Divya Bhargav1, Aiqun Wei1, Lisa A Williams1, Helen Tao2, David D F Ma2 and Ashish D 
Diwan1  
1.  Orthopaedic Research Institute and Department of Orthopaedic Surgery, St George Hospital, University of New South 
Wales, Sydney, Australia 
2.  Blood Stem Cell and Cancer Research Unit, Department of Haematology, St. Vincent’s Hospital Sydney, University of 
New South Wales, Sydney, Australia   

 Correspondence to: Dr Bojiang Shen, Orthopaedic Research Institute, St George Clinical School, The University of New 
South Wales, 4-10 South Street, Kogarah, NSW 2217. Tel: 61-2-9113 2248; Fax: 61-2-9350 3967; E-mail: b.shen@unsw.edu.au 
Received: 2008.12.17; Accepted: 2009.02.09; Published: 2009.02.13 
Abstract 
Bone morphogenetic protein-13 (BMP-13) plays an important role in skeletal development. 
In the light of a recent report that mutations in the BMP-13 gene are associated with spine 
vertebral fusion in Klippel-Feil syndrome, we hypothesized that BMP-13 signaling is crucial 
for regulating embryonic endochondral ossification. In this study, we found that BMP-13 in-
hibited the osteogenic differentiation of human bone marrow multipotent mesenchymal 
stromal cells (BM MSCs) in vitro. The endogenous BMP-13 gene expression in MSCs was 
examined under expansion conditions. The MSCs were then induced to differentiate into 
osteoblasts in osteo-inductive medium containing exogenous BMP-13. Gene expression was 
analysed by real-time PCR. Alkaline phosphatase (ALP) expression and activity, proteoglycan 
(PG) synthesis and matrix mineralization were assessed by cytological staining or ALP assay. 
Results showed that endogenous BMP-13 mRNA expression was higher than BMP-2 or -7 
during MSC growth. BMP-13 supplementation strongly inhibited matrix mineralization and 
ALP activity of osteogenic differentiated MSCs, yet increased PG synthesis under the same 
conditions. In conclusion, BMP-13 inhibited osteogenic differentiation of MSCs, implying that 
functional mutations or deficiency of BMP-13 may allow excess bone formation. Our finding 
provides an insight into the molecular mechanisms and the therapeutic potential of BMP-13 
in restricting pathological bone formation. 
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1. Introduction 
 
Bone morphogenetic proteins (BMPs) are mem-
bers of the transforming growth factor-β (TGF-β) su-
perfamily, which includes the families of TGF-βs, 
BMPs, activins and inhibins. BMPs were originally 
identified because of their ability to induce endo-
chondral bone formation and are important regulators 
of key events in the process of bone formation during 
embryogenesis, postnatal growth, remodelling and 
regeneration of the skeleton [1, 2, 3]. Recombinant 
human BMP-2 and BMP-7 are used clinically to aug-
ment bone formation in spinal fusion and many other 
applications in which bone induction is desired [4]. 
BMP-13, also known as growth differentiation 
factor 6 (GDF6) and cartilage-derived morphogenetic 
protein-2 (CDMP-2), was first identified and isolated 
as a component of bovine cartilage [5]. Expression of 
BMP-13 has since been detected in a variety of mes-
enchymal derivatives such as tendon and cartilage, 
but its biological function is poorly defined [6]. The 
majority of studies focus on connective tissue healing 
where de-novo implantation of BMP-13 induces 
neo-tendon/ligament formation in rats [7][8], and the 
expression of chondrocyte markers such as pro-Int. J. Biol. Sci. 2009, 5 
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teoglycans [6]. Comparisons with other BMPs known 
for their ability to stimulate bone growth have sug-
gested that BMP-13 is not strongly osteo-inductive [9, 
10, 11, 12]. Indeed, BMP-13 expression was absent 
from osteoblasts or newly formed osteocytes, rather 
BMP-13 was strongly detected in chondrocytes in a 
human osteophyte (bone spur) study [13]. In vivo, 
mutational inactivation of the BMP-13 gene is associ-
ated with Klippel-Feil syndrome (KFS), characterised 
by congenital fusion of the cervical spine vertebrae 
[14], and caused defects in joint, ligament, and carti-
lage formation in a transgenic mouse model [15].  
The function of BMPs in bone remodelling and 
fracture repair is associated with the recruitment of 
stem cells from surrounding tissues and with effects 
on the osteogenic lineage commitment of these cells. 
Bone marrow multipotent mesenchymal stromal cells 
(BM MSCs) are capable of differentiating into multi-
ple cell types including osteoblasts and chondrocytes, 
which makes them an attractive cell source for tissue 
repair. We need to understand the complex differen-
tiation pathways driven by multiple growth factors in 
order to select appropriate growth factors for clinical 
use.  
Given the phenotypic effects of joint fusions and 
joint aberrations caused by BMP-13 mutations [14], 
we hypothesized that BMP-13 plays an important 
regulatory role in the balance between osteogenesis 
and chondrogenesis during early embryonic devel-
opment. The purpose of this study was to evaluate the 
role of BMP-13 in determining the lineage fate of BM 
MSCs. BMP-13 was found to inhibit osteogenic dif-
ferentiation, demonstrated by the deceleration of cal-
cium mineralisation of the extracellular matrix and 
reduced alkaline phosphatase induction in BM MSCs. 
BMP-7, known to be a potent osteo-inductive agent 
[16], was used as a positive control throughout the 
study. Our data suggest a potential role of BMP-13 in 
directing stem cell fates in the development of struc-
tural tissues.  
2. Materials and Methods 
Cell isolation and cultivation 
Human bone marrow was collected from surgi-
cally discarded tissue during hip replacement proce-
dures under written informed consent following local 
ethics committee approval. BM MSCs were isolated 
by the antibody mediated negative selection, Fi-
coll-Paque density gradient centrifugation and plastic 
adherence as previously described [17]. The cells were 
cultured in growth medium (GM) consisting of 60% 
Dulbecco’s Modified Eagle’s Medium – low glucose 
(DMEM-LG; Invitrogen, Carlsbad, CA, USA), 40% 
MCDB-201 medium, 1% insulin transferrin selenium 
(ITS), 1% linoleic acid / bovine serum albumin (BSA), 
1 nM dexamethasone, 30 µg/ml ascorbic acid 
2-phosphate (Sigma-Aldrich, St. Louis, MO, USA), 100 
U/ml penicillin, 100 µg/ml streptomycin and 10% 
foetal bovine serum (FBS). The cells were incubated at 
37°C in a humidified atmosphere with 5% CO2. The 
medium was changed twice weekly. 
Osteogenic differentiation 
BM MSCs at Passage 2 - 3 were harvested using a 
standard method. For osteogenic differentiation, 1 x 
105 cells per well of BM MSCs were seeded in 24-well 
culture plates. The MSCs were induced approxi-
mately 24 hours later using the published method [18] 
with the osteo-inductive medium (OM) consisting of 
DMEM-LG, 10% FBS, 10 mM β-glycerophosphate, 100 
nM dexamethasone, 50 µg/ml ascorbic 
acid-2-phosphate, 100 U/ml penicillin and 100 µg/ml 
streptomycin in the absence or presence of recombi-
nant human (rh) BMP-13 (PeproTech, Rocky Hill, NJ) 
at 100, 300 and 500 ng/ml. Undifferentiated MSCs 
were cultured in parallel in growth medium as nega-
tive control. As for the positive control, MSCs were 
induced in osteo-inductive medium supplemented 
with 100 ng/ml of rhBMP-7 (a gift from Stryker Bio-
tech). Cells were kept at 37°C, 5% CO2 for up to 21 
days and the media were changed twice weekly. 
Cytological staining 
Alkaline phosphatase (ALP) expression as the 
early osteogenic marker was determined at day 14 of 
MSC differentiation using Fast blue staining. Calcium 
mineralization of extracellular matrix was visualized 
at days 14 and 21 as an advanced osteogenic marker 
using Alizarin red S staining. Briefly, the cell layers of 
differentiated MSCs were washed with phos-
phate-buffered saline (PBS), fixed with 4% parafor-
maldehyde for 5 min. The membrane-bound ALP was 
detected by incubation in 0.1% Fast blue RR salt and 
naphthol AS-BI phosphate solution at pH 9.4, 37ºC for 
20 min. For Alizarin red S staining, the cells were 
washed and fixed as above and then immersed in the 
2% Alizarin red S solution at pH 4.2 for 10 min fol-
lowed by 3 washes in H2O. Proteoglycan (PG) depo-
sition in the presence and absence of BMP-13 was 
detected by staining with 1% Alcian blue at day 14 of 
culture using a previously reported method [19]. 
Alkaline phosphatase assay 
  BM MSCs were induced to osteogenic differen-
tiation under the above described osteogenic induc-
tion conditions with supplementation of 3 - 800 ng/ml 
of BMP-13 (Peprotech) at 37ºC, 5% CO2 for 14 days. 
Cells were washed with PBS and then lysed for 1 h Int. J. Biol. Sci. 2009, 5 
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with 100 µl of 1% NP40 in ALP buffer (0.1 M glycine, 
pH 9.6, 1 mM MgCl2, 1 mM ZnCl2). ALP activity was 
determined by incubating lysed cells with 100 µl of 
p-Nitrophenyl phosphate substrate solution 
(Sigma-Aldrich) for 10 min and measuring the ab-
sorbance at 405 nm [20]. 
 
RNA extraction, cDNA synthesis and real-time PCR 
Total RNA was isolated from undifferentiated 
and differentiated MSCs using TRIzol reagent (Invi-
trogen) and RNeasy kit (Qiagen, Dusseldorf, Ger-
many) following manufacturers’ instructions. cDNA 
was generated by reverse transcription of 1 µg total 
RNA using SuperScript III first-strand synthesis kit 
(Invitrogen). The 1:40 diluted cDNA was used in 20 
µl-reactions for real-time PCR analysis using a Ro-
tor-Gene RG3000 system (Corbett Life Science, Syd-
ney). The thermal profile for all reactions was as fol-
lows: 5 min at 95°C, followed by 40 amplification cy-
cles of 15 sec at 95°C, 30 sec at 60°C and 30 sec at 72°C 
[19]. The GenBank access numbers, real-time PCR 
primer pairs and product sizes are listed in Table 1. 
Relative expression levels were calculated as a ratio to 
the average value of house-keeping genes, glyceral-
dehyde-3-phosphate dehydrogenase  (GAPDH)  and 
hypoxanthine phosphoribosyltransferase 1 (HPRT1). 
 
 
TABLE 1. Primer pairs used for real-time PCR. 
Gene 
Symbol 
GenBank Accession Number  Sequence (5’ – 3’)  Product Size 
(bp) 
F – TTTCCATGTGGACGCTCTTT  BMP2 NM_001200   
R - GGAAGCAGCAACGCTAGAAG 
118 
F - GAGTGTGCCTTCCCTCTGAA   BMP7 NM_001719   
R - TAGAGGACGGAGATGGCATT  
140 
F - TGCCAGCTTTTTCCAGTCTT   BMP13 NM_001001557   
R - AGGAGTGTGCGAGAGATCGT  
85 
F – GACAAGAAGCCCTTCACTGC  ALPL NM_000478   
R - AGACTGCGCCTGGTAGTTGT 
120 
F – GGCGCTACCTGTATCAATGG  BGLAP NM_199173 
R - TCAGCCAACTCGTCACAGTC 
106 
F – GAGAGCATGACCGATGGATT  COL1A1 NM_000088 
R - ATGTAGGCCACGCTGTTCTT  
149 
F - ATGTCTTGCCCCAAGATGTC   SP7 NM_152860   
R - TATCCACCACTACCCCCAGT  
115 
F – GCCGAGGTGATAGTGTGGTT  SPP1 NM_000582   
R - TGAGGTGATGTCCTCGTCTG 
101 
F - GCCTAGGCGCATTTCAGA    RUNX2 NM_004348   
R - CTGAGAGTGGAAGGCCAGAG  
66 
F – CAGCAATGTGGATGAGATGG  TAZ NM_015472   
R - TGGGGATTGATGTTCATGG   
66 
F - AGCGAGATCAAAGGGCTAGA   NOG NM_005450   
R - TGTAACTTCCTCCGCAGCTT  
86 
F – AATCCCATCACCATCTTCCA  GAPDH NM_002046 
R - TGGACTCCACGACGTACTCA 
82 
F – GACCAGTCAACAGGGGACAT  HPRT1 NM_000194 
R - CCTGACCAAGGAAAGCAAAG 
132 
 
 
Statistics 
Data is presented as the mean ± Standard Devia-
tion (SD). Statistical analyses were performed using 
the Student’s t test to analyse gene expression data. 
Differences between undifferentiated (CTL) and dif-
ferentiated (OM, BMP7 or BMP13) BM MSCs were 
considered statistically significant at p < 0.05 (*), p < 
0.01 (**) and p < 0.005 (***). 
3. Results and Discussion 
BMP-13 gene expression in BM MSCs 
  BM MSCs grown in monolayer culture in 
growth medium containing 10% FBS were harvested 
at days 1, 3, 5, and 7 for gene expression analysis (Fig. 
1). The endogenous expression of BMP-13 was de-
tected at all time points, showing considerably higher Int. J. Biol. Sci. 2009, 5 
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l e v e l s  t h a n  e i t h e r  B M P - 2  o r  B M P - 7 .  E x p r e s s i o n  i n -
creased over time, peaking at day 5-7. Whilst litera-
ture reports indicate BMP-13 expression in a variety of 
tissues localised to sites of cell proliferation or tissue 
re-modelling [6], BMP-13 expression in BM MSCs has 
only previously been reported in mouse [21]. Our 
finding suggests an important regulatory role of 
BMP-13 in BM MSCs which might be different from 
the other more osteogenic BMPs. 
BMP-13 inhibits osteogenic differentiation of BM MSCs 
Cytological staining with Fast blue and Alizarin 
r e d  S  s h o w e d  t h a t  B M  M S C s  c u l t u r e d  i n  o s -
teo-inductive medium for 14-21 days were differenti-
ated into osteoblasts, with elevated expression of cell 
surface alkaline phosphatase (ALP) and calcium 
mineralisation of the extracellular matrix compared to 
MSCs grown under expansion conditions where 
staining was negligible (Fig. 2). Addition of BMP-13 at 
100, 300 and 500 ng/ml in osteo-inductive medium 
resulted in a dose-dependent decrease in detectable 
ALP (Fig. 2A). A parallel dose dependent inhibition of 
calcium mineralisation, a later marker of osteogenic 
differentiation, was observed using Alizarin red S 
staining over both 14 and 21 days (Fig. 2B and C). In 
contrast, 100 ng/ml of BMP-7 dramatically increased 
both ALP expression and matrix mineralization in 
osteo-differentiated MSCs at day 14 (Fig. 2B) and day 
21 (Fig. 2C), which represents an enhancement or ac-
celeration of osteogenic differentiation under these 
conditions. Whilst not shown here, BMP-7 enhance-
ment of osteogenic differentiation is also 
dose-dependent (data not shown; Shen et al 2008, 
manuscript in preparation). The effect of BMP-13 on 
ALP in MSCs was further illustrated in measurements 
of ALP activity (Fig. 2D). BMP-13 dose dependently 
inhibited ALP activity to a maximum of 40%, con-
firming the results obtained from Fast blue staining 
(Fig 2A).   
 
 
 
 
 
Figure 1. Endogenous BMP-13 gene expression in undifferentiated BM MSCs by real-time PCR analysis. BMP-13 gene 
expression was detected at days 1, 3, 5 and 7 in MSC expansion cultures and compared to that of BMP-2 and -7 in parallel. 
Relative expression was calculated as a ratio to the average value of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
and hypoxanthine phosphoribosyltransferase 1 (HPRT1). The individual BMP-2 and -7 time-course expression levels are 
shown in insets.  Int. J. Biol. Sci. 2009, 5 
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Figure 2. Effects of BMP-13 on alkaline phosphatase (ALP) expression and matrix mineralization of osteogenic differenti-
ated BM MSCs by cytological staining. MSC differentiation was induced in osteo-inductive medium and supplemented with 
100, 300, and 500 ng/ml of BMP-13 or 100 ng/ml of BMP-7 respectively for 14-21 days. Active ALP was detected by a blue 
cleavage product using a Fast blue RR salt dye (A). Matrix mineralization was visualised by Alizarin red S staining at days 14 
(B) and 21 (C). Undifferentiated MSCs were used as the negative control. CTL = undifferentiated negative control; OM = 
osteo-inductive medium; BMP-7 = OM+BMP-7; BMP-13 = OM+BMP-13 for all figures. The BMP concentrations at ng/ml are 
listed in brackets. Original magnification x 100 for all images. ALP activity was measured in MSCs after 14 days differentiation 
in osteo-inductive medium with or without BMP-13 (3-800 ng/ml). ALP activity is represented as A405 mean values from 
quadruplicate cultures (D).  
 
Our results demonstrate that the presence of 
BMP-13 in osteo-inductive media can, despite an en-
vironment promoting osteogenic differentiation, 
prevent MSCs from differentiating into a mature os-
teogenic phenotype. This represents a dramatically 
different role for BMP-13 to the better characterised 
BMP-2 and BMP-7. BMP-13 was shown to enhance 
BMP-7 promoted ALP expression in mouse myoblast 
cell line C2C12 [9], but BMP-13 stimulation of ALP 
activity was generally at negligible to low levels in 
mouse BM MSCs or cell lines cultured in basal growth 
media [9, 10, 11, 21, 22]. Unlike previous studies, we 
have utilised primary human BM MSCs and the effect 
of BMP-13 was examined during the osteogenic dif-
ferentiation of BM MSCs. Such a model system has 
not been previously studied and may provide deeper Int. J. Biol. Sci. 2009, 5 
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insights into BMP-13 function. Actually, recent re-
ports have suggested that BMP-13 was capable of 
inducing the chondrogenic differentiation of mouse 
mesenchymal stromal or progenitor cells, based on 
increased chondrocytic marker expression [23][22]. 
Instead of promoting bone formation, BMP-13 is more 
likely to be a potential factor for maintaining cartilage 
development. Thus, 
whilst previous reports 
have suggested BMP-13 
is not a potent osteogenic 
differentiation inducer 
(9, 10), our data goes one 
step further in showing 
that BMP-13 can inhibit 
osteoblast formation. 
This implies that func-
tional mutations or defi-
ciency of BMP-13 may 
result in excessive en-
dochondral ossification, 
disturbing the develop-
ment of skeletal tissues.  
The regulatory role of 
BMP-13 in osteogenic gene 
expression of BM MSCs  
In order to evaluate more specifically the poten-
tial mechanism of BMP-13 in the inhibition of osteo-
genic differentiation of BM MSCs, we performed gene 
expression analysis of markers for osteogenesis using 
real-time PCR assay (Fig. 3).  
 
 
Figure 3. Gene expression 
analysis of osteogenic 
markers and BMP antago-
nists in differentiated BM 
MSCs by real-time PCR 
analysis. The osteogenic 
differentiation of BM MSCs 
was induced by os-
teo-inductive media in the 
presence and absence of 
100 ng/ml BMP-7 or 300 
ng/ml BMP-13 for 14 days. 
Undifferentiated MSCs 
were used as negative con-
trol. The gene expression 
level was calculated as a 
relative ratio to the average 
value of house-keeping 
genes, GAPDH and HPRT1. 
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Osteogenic medium alone induced the 
up-regulation of specific lineage marker expression 
[14, 15] such as alkaline phosphatase (ALPL), bone 
gamma-carboxyglutamate (gla) protein (BGLAP), 
runt-related transcription factor 2 (RUNX2), and TAZ 
(WW-domain-containing transcription regulator 1, 
WWTR1) (Fig. 3). The addition of BMP-13 inhibited 
ALPL mRNA expression, consistent with the ALP 
protein staining data discussed above. BMP-13 had no 
effect on the expression of crucial osteogenic tran-
scription factor, osterix (SP7), whereas BMP-7 dra-
matically increased its expression by 1300-fold (Fig. 
3). BMP-13 also showed considerably less induction of 
osteogenic markers, type I collagen (COL1A1), osteo-
pontin (secreted phosphoprotein 1, SPP1) and RUNX2 
compared to BMP-7 in the same experiment. BMP-13 
somewhat surprisingly mediated up-regulation of 
SPP1 mRNA, although once again this was also to a 
much lower level than stimulated by BMP-7, where 
SPP1 was dramatically up-regulated. BMP-7 also in-
duced up-regulation of BMP-2 expression, suggesting 
a potential mechanism for BMP-7 action via augmen-
tation of BMP-2. BMP-13 gene expression was similar 
whether BM MSCs were cultured in growth medium 
or osteo-inductive medium. BMP-13 supplementation 
appeared to up-regulate its own gene expression un-
der the osteogenic conditions. Additionally, the gene 
expression of noggin (NOG), a BMP antagonist, seems 
less responsive to BMP-13 than to BMP-7 stimulation 
(Fig. 3). 
In summary, the gene expression analysis 
showed that BMP-13 down-regulated or failed to 
up-regulate crucial osteogenic marker gene expres-
sion, when compared to the gene expression pattern 
obtained with BMP-7 stimulation. BMP-13 was sub-
stantially less inductive of osteogenic marker genes, 
and the resulting phenotypic effect detected in cyto-
logical staining experiments suggests that such level 
of gene expression did not enhance the osteogenic 
differentiation process.  
BMP-13 promotes proteoglycan synthesis of BM MSCs 
Proteoglycan (PG) synthesis or accumulation in 
the extracellular matrix has been used as a marker of 
chondrogenesis of BM MSCs and BMP-13 has been 
shown to stimulate PG production [6, 11, 24]. In this 
study, we evaluated PG levels in the osteogenic dif-
ferentiation of BM MSCs supplemented with BMP-13 
usin g Alcian  blue stainin g. As shown  in Fig. 4, th e 
presence of BMP-13 resulted in increased PG deposi-
tion or accumulation in the extracellular matrix of not 
only undifferentiated MSCs in growth medium, but 
even differentiated MSCs under specific os-
teo-inductive conditions.   
 
 
Figure 4. Effect of BMP-13 on proteoglycan accumulation 
in the extracellular matrix of BM MSCs detected by a cy-
tological staining. MSCs were cultured in growth medium 
(GM) and osteogenic differentiation medium (OM) with or 
without 300 ng/ml of BMP-13 for 14 days. At the termina-
tion of cultures, the cells were stained with Alcian blue to 
visualise the proteoglycans. Original magnification x 100 for 
all images. 
 
  The data presented here suggest that in the 
presence of BMP-13, osteo-inductive signaling is in-
hibited or retarded, whilst expression of more chon-
drogenic gene products is promoted. By inference, the 
absence of BMP-13 signaling at crucial stages of dif-
ferentiation could be expected to cause an 
over-induction of osteogenic cell phenotypes, con-
tributing to abnormal endochondral ossification of 
cartilaginous tissue. Strong expression of BMP-13 in 
the BM MSC population may play an important role 
in keeping osteogenic differentiation in check. Several 
studies have shown that BMP-13 is capable of induc-
ing chondrogenic phenotypes, characterised by in-
creased proteoglycan production in human foetal 
chondrocytes [11] and a mouse chondrocytic cell line 
[24]. BMP-13 is known to be expressed in the joints of 
mice in a particular striped pattern [15, 25] and muta-
tions in BMP-13 gene are implicated in sporadic and 
familial cases of KFS, characterised by the spinal ver-
tebral fusion [14]. 
In conclusion, this study demonstrates for the 
first time that BMP-13 potentially plays a crucial role 
in the delineation of BM MSC differentiation by in-
hibiting osteogenic lineage development, suggesting 
that functional mutations or deficiency of BMP-13 
may result in excessive endochondral ossification. 
Our finding provides a clue into the possible mo-Int. J. Biol. Sci. 2009, 5 
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lecular mechanisms of BMP-13 associated diseases 
and the therapeutic potential of BMP-13 in restricting 
pathological bone formation.   
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